Inflammasome Inhibition

Project Description

Inflammasomes are potent drivers of inflammatory responses, and are thus important for microbial clearance. But uncontrolled or inappropriate inflammatory responses are responsible for a wide variety of human diseases (e.g. septic shock, gout, diabetes, neurodegenerative diseases, various cancers). Cellular mechanisms of inflammasome inhibition are poorly characterised but of key importance to human health. New pharmacological approaches for inflammasome inhibition have broad potential for the treatment of human inflammatory and neurodegenerative diseases.

 

Projects:

  • Negative regulation of caspase activity
  • Inflammasome destruction by autophagy
  • New drugs to treat inflammasome-driven disease

 

Select Publications:

  1. Kimura T, Jain A, Choi SW, Mandell MA, Schroder K, Johansen T, Deretic V (2015).
    TRIM-mediated precision autophagy targets cytoplasmic regulators of innate immunity. Journal of Cell Biology 210(6):973-89. Pubmed
     
  2. Coll RC, Robertson AAB, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, Croker DE, Butler MS, Haneklaus M, Sutton CE, Núñez G, Latz E, Kastner DL, Mills KHG, Masters SL, Schroder K, Cooper MA, O’Neill LAJ (2015).
    A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine 21(3):248-55. Pubmed

 

Image: Artwork representing inactivation of inflammasomes.

Categories: 
Cell biology
In vivo biology
Molecular biology